AP570A - Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. - Google Patents

Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. Download PDF

Info

Publication number
AP570A
AP570A APAP/P/1993/000502A AP9300502A AP570A AP 570 A AP570 A AP 570A AP 9300502 A AP9300502 A AP 9300502A AP 570 A AP570 A AP 570A
Authority
AP
ARIPO
Prior art keywords
hepatitis
antigen
vaccine
hbsag
mpl
Prior art date
Application number
APAP/P/1993/000502A
Other languages
English (en)
Other versions
AP9300502A0 (en
Inventor
Nathalie Marie-Josephe Claude Garcon-Johnson
Pierre Hauser
Clothidle Thiriart
Pierre Voet
Original Assignee
Smithkline Beecham Biologicals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Application filed by Smithkline Beecham Biologicals S A filed Critical Smithkline Beecham Biologicals S A
Publication of AP9300502A0 publication Critical patent/AP9300502A0/xx
Application granted granted Critical
Publication of AP570A publication Critical patent/AP570A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
APAP/P/1993/000502A 1992-03-27 1993-03-25 Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. AP570A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine

Publications (2)

Publication Number Publication Date
AP9300502A0 AP9300502A0 (en) 1993-04-30
AP570A true AP570A (en) 1996-11-29

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000502A AP570A (en) 1992-03-27 1993-03-25 Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A.

Country Status (28)

Country Link
EP (1) EP0633784B2 (zh)
JP (1) JP3470719B2 (zh)
KR (1) KR100270134B1 (zh)
CN (1) CN1072963C (zh)
AP (1) AP570A (zh)
AT (1) ATE146678T1 (zh)
AU (4) AU3751693A (zh)
CA (1) CA2132833C (zh)
CZ (1) CZ283424B6 (zh)
DE (1) DE69306940T3 (zh)
DK (1) DK0633784T4 (zh)
ES (1) ES2098029T5 (zh)
FI (1) FI110843B (zh)
GR (1) GR3022174T3 (zh)
HK (1) HK1003218A1 (zh)
HU (1) HU221253B1 (zh)
IL (1) IL105161A (zh)
MA (1) MA22842A1 (zh)
MY (1) MY111880A (zh)
NO (1) NO309458B1 (zh)
NZ (1) NZ249868A (zh)
RU (1) RU2121849C1 (zh)
SA (1) SA93130573B1 (zh)
SG (1) SG48375A1 (zh)
SI (1) SI9300149B (zh)
SK (1) SK280160B6 (zh)
UA (1) UA44688C2 (zh)
WO (1) WO1993019780A1 (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
NZ506602A (en) * 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
US7357936B1 (en) * 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
KR101505496B1 (ko) 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
EP1863529A1 (en) 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
EP2368572B1 (en) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP1973564B1 (en) 2005-12-22 2016-11-09 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP6087041B2 (ja) 2006-01-27 2017-03-08 ノバルティス アーゲー 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2497495B3 (en) 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2679240A1 (en) 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US20100183662A1 (en) 2007-06-26 2010-07-22 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2235532B1 (en) 2007-12-24 2013-04-24 Novartis AG Assays for adsorbed influenza vaccines
US20120058149A1 (en) 2009-03-05 2012-03-08 Mccloskey Jenny Colleen Treatment of infection
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EA025152B1 (ru) 2010-12-02 2016-11-30 Бионор Иммуно Ас Конструкция пептидного каркаса
MX346475B (es) 2011-01-06 2017-03-22 Bionor Immuno As Peptidos inmunogenicos monomericos y multimericos.
EP2667892B1 (en) 2011-01-26 2019-03-27 GlaxoSmithKline Biologicals SA Rsv immunization regimen
LT3275892T (lt) 2011-05-13 2020-04-10 Glaxosmithkline Biologicals S.A. Struktūros prieš suliejimą rsv f antigenai
CN104619718A (zh) 2012-06-06 2015-05-13 比奥诺尔免疫有限公司 源自病毒蛋白的肽用作免疫原和配药成分
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
US12128100B2 (en) 2018-11-13 2024-10-29 Variation Biotechnologies Inc. Immunogenic compositions for treatment of Hepatitis B
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261A2 (en) * 1984-09-12 1986-03-26 Chiron Corporation Hybrid particle immunogens
GB2220211A (en) * 1988-06-29 1990-01-04 Ribi Immunochem Research Inc Modified lipopolysaccharides
WO1991016926A1 (en) * 1990-05-07 1991-11-14 North American Vaccine, Inc. Vaccine compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049686C (zh) * 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
SG48175A1 (en) * 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
WO1992011291A1 (en) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261A2 (en) * 1984-09-12 1986-03-26 Chiron Corporation Hybrid particle immunogens
GB2220211A (en) * 1988-06-29 1990-01-04 Ribi Immunochem Research Inc Modified lipopolysaccharides
WO1991016926A1 (en) * 1990-05-07 1991-11-14 North American Vaccine, Inc. Vaccine compositions

Also Published As

Publication number Publication date
CN1085805A (zh) 1994-04-27
KR950700757A (ko) 1995-02-20
RU94042386A (ru) 1996-08-20
HK1003218A1 (en) 1998-10-16
FI944442A (fi) 1994-09-26
KR100270134B1 (ko) 2000-10-16
DK0633784T4 (da) 2001-12-31
IL105161A (en) 1998-08-16
ES2098029T5 (es) 2002-03-16
SK280160B6 (sk) 1999-09-10
AU1000802A (en) 2002-02-21
AU3397499A (en) 1999-08-19
IL105161A0 (en) 1993-07-08
SA93130573B1 (ar) 2004-08-31
CA2132833A1 (en) 1993-10-14
DE69306940D1 (de) 1997-02-06
EP0633784B2 (en) 2001-10-17
AU6445796A (en) 1996-11-07
CZ235594A3 (en) 1995-02-15
NZ249868A (en) 1997-03-24
AU767755B2 (en) 2003-11-20
UA44688C2 (uk) 2002-03-15
HU9402758D0 (en) 1994-12-28
DK0633784T3 (da) 1997-01-20
GR3022174T3 (en) 1997-03-31
SI9300149B (sl) 2003-02-28
CZ283424B6 (cs) 1998-04-15
AU3751693A (en) 1993-11-08
JPH07505372A (ja) 1995-06-15
ES2098029T3 (es) 1997-04-16
HUT69931A (en) 1995-09-28
DE69306940T3 (de) 2002-09-19
MA22842A1 (fr) 1993-10-01
DE69306940T2 (de) 1997-06-26
FI944442A0 (fi) 1994-09-26
EP0633784B1 (en) 1996-12-27
ATE146678T1 (de) 1997-01-15
CA2132833C (en) 2007-03-06
CN1072963C (zh) 2001-10-17
RU2121849C1 (ru) 1998-11-20
SK115294A3 (en) 1995-06-07
WO1993019780A1 (en) 1993-10-14
NO943571D0 (no) 1994-09-26
FI110843B (fi) 2003-04-15
JP3470719B2 (ja) 2003-11-25
NO309458B1 (no) 2001-02-05
AP9300502A0 (en) 1993-04-30
EP0633784A1 (en) 1995-01-18
SI9300149A (en) 1993-12-31
HU221253B1 (en) 2002-09-28
NO943571L (no) 1994-11-14
SG48375A1 (en) 1998-04-17
MY111880A (en) 2001-02-28

Similar Documents

Publication Publication Date Title
AP570A (en) Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A.
AP766A (en) A vaccine based on hepatitis B antigen.
AP515A (en) "Vaccine compositions".
US6893644B2 (en) Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A
US6488934B1 (en) Hepatitis B vaccine